Cargando…

Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations

The COVID-19 pandemic, which began in Wuhan (Hubei, China), has been ongoing for about a year and a half. An unprecedented number of people around the world have been infected with SARS-CoV-2, the etiological agent of COVID-19. Despite the fact that the mortality rate for COVID-19 is relatively low,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gladkikh, Anna, Dolgova, Anna, Dedkov, Vladimir, Sbarzaglia, Valeriya, Kanaeva, Olga, Popova, Anna, Totolian, Areg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230012/
https://www.ncbi.nlm.nih.gov/pubmed/34072569
http://dx.doi.org/10.3390/v13061029
_version_ 1783713107006193664
author Gladkikh, Anna
Dolgova, Anna
Dedkov, Vladimir
Sbarzaglia, Valeriya
Kanaeva, Olga
Popova, Anna
Totolian, Areg
author_facet Gladkikh, Anna
Dolgova, Anna
Dedkov, Vladimir
Sbarzaglia, Valeriya
Kanaeva, Olga
Popova, Anna
Totolian, Areg
author_sort Gladkikh, Anna
collection PubMed
description The COVID-19 pandemic, which began in Wuhan (Hubei, China), has been ongoing for about a year and a half. An unprecedented number of people around the world have been infected with SARS-CoV-2, the etiological agent of COVID-19. Despite the fact that the mortality rate for COVID-19 is relatively low, the total number of deaths has currently already reached more than three million and continues to increase due to high incidence. Since the beginning of the pandemic, a large number of sequences have been obtained and many genetic variants have been identified. Some of them bear significant mutations that affect biological properties of the virus. These genetic variants, currently Variants of Concern (VoC), include the so-called United Kingdom variant (20I/501Y), the Brazilian variant (20J/501Y.V3), and the South African variant (20H/501Y.V2). We describe here a novel SARS-CoV-2 variant with distinct spike protein mutations, first obtained at the end of January 2021 in northwest Russia. Therefore, it is necessary to pay attention to the dynamics of its spread among patients with COVID-19, as well as to study in detail its biological properties.
format Online
Article
Text
id pubmed-8230012
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82300122021-06-26 Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations Gladkikh, Anna Dolgova, Anna Dedkov, Vladimir Sbarzaglia, Valeriya Kanaeva, Olga Popova, Anna Totolian, Areg Viruses Communication The COVID-19 pandemic, which began in Wuhan (Hubei, China), has been ongoing for about a year and a half. An unprecedented number of people around the world have been infected with SARS-CoV-2, the etiological agent of COVID-19. Despite the fact that the mortality rate for COVID-19 is relatively low, the total number of deaths has currently already reached more than three million and continues to increase due to high incidence. Since the beginning of the pandemic, a large number of sequences have been obtained and many genetic variants have been identified. Some of them bear significant mutations that affect biological properties of the virus. These genetic variants, currently Variants of Concern (VoC), include the so-called United Kingdom variant (20I/501Y), the Brazilian variant (20J/501Y.V3), and the South African variant (20H/501Y.V2). We describe here a novel SARS-CoV-2 variant with distinct spike protein mutations, first obtained at the end of January 2021 in northwest Russia. Therefore, it is necessary to pay attention to the dynamics of its spread among patients with COVID-19, as well as to study in detail its biological properties. MDPI 2021-05-29 /pmc/articles/PMC8230012/ /pubmed/34072569 http://dx.doi.org/10.3390/v13061029 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Gladkikh, Anna
Dolgova, Anna
Dedkov, Vladimir
Sbarzaglia, Valeriya
Kanaeva, Olga
Popova, Anna
Totolian, Areg
Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title_full Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title_fullStr Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title_full_unstemmed Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title_short Characterization of a Novel SARS-CoV-2 Genetic Variant with Distinct Spike Protein Mutations
title_sort characterization of a novel sars-cov-2 genetic variant with distinct spike protein mutations
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230012/
https://www.ncbi.nlm.nih.gov/pubmed/34072569
http://dx.doi.org/10.3390/v13061029
work_keys_str_mv AT gladkikhanna characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT dolgovaanna characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT dedkovvladimir characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT sbarzagliavaleriya characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT kanaevaolga characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT popovaanna characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations
AT totolianareg characterizationofanovelsarscov2geneticvariantwithdistinctspikeproteinmutations